

- **Name:** Stephen L. CHAN
 - **Current Position & Affiliation:** Associate (Clinical) Professor at the Department of Clinical Oncology of the Chinese University of Hong Kong
 - **Country:** Hong Kong
-

• Educational Background:

Bachelor of Medicine and Bachelor of Surgery (The University of Hong Kong) (2000)
Membership of the Royal College of Physicians (United Kingdom) (2003)
Fellowship of Hong Kong College of Physicians (2007)
Fellowship of Hong Kong Academy of Medicine (Medicine) (2007)
Fellowship of Royal College of Physician (Edinburgh) (2014)
Fellowship of Royal College of Physician (London) (2016)
Doctor of Medicine (The Chinese University of Hong Kong) (2018)

• Professional Experience:

Resident, Department of Clinical Oncology, Prince of Wales Hospital (Jul 2001 - Jun 2007)
Resident Specialist, Department of Clinical Oncology, Prince of Wales Hospital (Jul 2007 - Mar 2008)
Assistant (Clinical) Professor, Department of Clinical Oncology, The Chinese University of Hong Kong (Mar 2008 - Feb 2014)
Associate (Clinical) Professor, Department of Clinical Oncology, The Chinese University of Hong Kong (Mar 2014 - Present)

• Professional Organizations:

Associate Editor for the Journal of Hepatology and editorial board members of Liver International
an international member of the NCI Hepatobiliary Task Force of the Gastrointestinal Steering Committee in United States

• Main Scientific Publications:

1. Abou-Alfa, G.K., Meyer, T., Cheng, A.L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.Y., Cicin, I., Merle, P., Chen, Y., Park, J.W., Blanc, J.F., Bolondi, L., Klümper, H.J., Chan, S.L., Zagonel, V., Pressiani, T., Ryu, M.H., Venook, A.P., Hessel, C., Borgman-Hagey, A.E., Schwab, G., & Kelley, R.K. (2018). Cabozantinib in patients with advanced

and progressing hepatocellular carcinoma. *N Engl J Med*, 379(1), 54-63. PMID: 29972759 (Impact factor: 79.258)

2. Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., Chan, S.L., Knox, J., Daniele, B., Webber, A.L., Ebbinghaus, S.W., Ma, J., Siegel, A.B., Cheng, A.L., Kudo, M., & KEYNOTE-224 investigators. (2018). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol*, 19(7), 940-952. PMID: 29875066 (Impact factor: 36.418)

3. Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., Yeo, W., Mo, F., Lai, P., Inarrairaegui, M., Chan, S.L., Sangro, B., Miksad, R., Tada, T., Kumada, T., & Toyoda, H. (2015). Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—The ALBI Grade. *J Clin Oncol*, 33(6), 550-558. PMID: 25512453 (Impact factor: 26.303)

4. Yeo, W., Chung, H.C., Chan, S.L., Wang, L.Z., Lim, R., Picus, J., Boyer, M., Mo, F.K., Koh, J., Rha, S.Y., Hui, E.P., Jeung, H.C., Roh, J.K., Yu, S.C., To, K.F., Tao, Q., Ma, B.B., Chan, A.W., Tong, J.H., Erlichman, C., Chan, A.T., & Goh, B.C. (2012). Epigenetic therapy using Belinostat for patients with unresectable hepatocellular carcinoma: A multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. *J Clin Oncol*, 30(27), 3361-3367. PMID: 22915658 (Impact factor: 26.303)

5. Li, X., Xu, W., Kang, W., Wong, S.H., Wang, M., Zhou, Y., Fang, X., Zhang, X., Yang, H., Wong, C.H., To, K.F., Chan, S.L., Chan, M.T.V., Sung, J.J.Y., Wu, W.K.K., & Yu, J. (2018). Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. *Theranostics*, 8(6), 1740-1751. PMID: 29556353 (Impact factor: 8.537)

6. Yu, S.C.H., Chan, S.L., Lee, K.F., Hui, J.W.Y., Hui, E.P., Chu, C.M., Chan, A.W., Cheung, S., Li, L., Wong, J., & Yeo, W.M.M. (2018). Ablative chemoembolization for hepatocellular carcinoma: a prospective phase I case-control comparison with conventional chemoembolization. *Radiology*, 287(1), 340-348. PMID: 29272212 (Impact factor: 7.469)

7. Margetts, J., Ogle, L.F., Chan, S.L., Chan, A.W.H., Chan, K.C.A., Jamieson, D., Willoughby, C.E., Mann, D.A., Wilson, C.L., Manas, D.M., Yeo, W., & Reeves, H.L. (2018). Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? *Br J Cancer*, 118(2), 248-257. PMID: 29123264 (Impact factor: 5.922)

8. Niu, L.L., Cheng, C.L., Li, M.Y., Yang, S.L., Hu, B.G., Chong, C.C.N., Chan, S.L., Ren, J., Chen, G.G., & Lai, P.B.S. (2018). ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. *Cell Death Dis*, 9, 852. PMID: 30154433 (Impact factor: 5.638)